Santen

Santen Launches SETANEO Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension

23 October 2025 -- Osaka, Japan -- Santen Pharmaceutical Co., Ltd announced today that it launched SETANEO Ophthalmic Solution 0.002% (generic name: sepetaprost; hereafter the product) in Japan, for the treatment of glaucoma and ocular hypertension. The product contains 0.002% sepetaprost, a bicyclic prostaglandin derivative, which binds to and stimulates FP and EP3 receptors, promoting...
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan

+81-6-7664-8621